SEC Form SC 13G/A filed by 10x Genomics Inc. (Amendment)
$TXG
Biotechnology: Laboratory Analytical Instruments
Industrials
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2025 | $25.00 → $12.00 | Outperform → Market Perform | Leerink Partners |
| 9/3/2024 | $35.00 | Outperform | Leerink Partners |
| 7/22/2024 | $24.00 | Hold → Buy | Jefferies |
| 7/18/2024 | $40.00 → $20.00 | Overweight → Neutral | JP Morgan |
| 7/10/2024 | $55.00 → $25.00 | Buy → Hold | Deutsche Bank |
| 6/27/2024 | Outperform → Peer Perform | Wolfe Research | |
| 6/25/2024 | Buy → Neutral | Guggenheim | |
| 6/3/2024 | $24.00 | Hold | Jefferies |
SCHEDULE 13G - 10x Genomics, Inc. (0001770787) (Subject)
SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
8-K - 10x Genomics, Inc. (0001770787) (Filer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
4 - 10x Genomics, Inc. (0001770787) (Issuer)
First fully integrated spatial multiomic assay from 10x Genomics brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology PLEASANTON, Calif., Aug. 19, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced the launch of Xenium Protein, a powerful new addition to its Xenium Spatial platform that enables simultaneous RNA and protein detection in the same cell, on the same tissue section, all in a single automated run. As the first fully integrated spatial multiomic workflow for the Xenium platform from 10x Genomics, Xenium Protein empowers researchers to generate deeper biological
PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2025. Recent Updates Revenue was $172.9 million for the second quarter. Excluding $27.3 million related to a patent litigation settlement, revenue was $145.6 million.Ended the second quarter with cash and cash equivalents and marketable securities of $447.3 million, representing a $20 million increase over the prior quarter.Entered into a definitive agreement to acquire Scale Biosc
Acquisition Will Further Expand Chromium's Capabilities PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced that it has signed a definitive agreement to acquire Scale Biosciences, Inc., a leader in innovative and scalable single cell analysis. The acquisition provides 10x with key inventions and technologies that will advance innovation across the company's Chromium platform. It also helps broaden access to single cell analysis by making it more powerful, affordable, and accessible to researchers worldwide.
4 - 10x Genomics, Inc. (0001770787) (Issuer)
Leerink Partners downgraded 10x Genomics from Outperform to Market Perform and set a new price target of $12.00 from $25.00 previously
Leerink Partners initiated coverage of 10x Genomics with a rating of Outperform and set a new price target of $35.00
Jefferies upgraded 10x Genomics from Hold to Buy and set a new price target of $24.00
SC 13G - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G - 10x Genomics, Inc. (0001770787) (Subject)
SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2025. Recent Updates Revenue was $172.9 million for the second quarter. Excluding $27.3 million related to a patent litigation settlement, revenue was $145.6 million.Ended the second quarter with cash and cash equivalents and marketable securities of $447.3 million, representing a $20 million increase over the prior quarter.Entered into a definitive agreement to acquire Scale Biosc
PLEASANTON, Calif., July 10, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the second quarter ended June 30, 2025 after market close on Thursday, August 7, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates Revenue was $154.9 million for the first quarter. Excluding $16.8 million related to a patent litigation settlement, revenue was $138.1 million, a 2% decrease from the corresponding period of 2024, primarily driven by a significant decrease in instrument revenue.Ended the first quarter with cash and cash equivalents and marketable securities of $426.9 million. As
PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer
Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an
Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today. Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the boar